Results from the FURTHER Trial Demonstrate Firmonertinib is a Promising Potential Therapy for Patients with NSCLC with EGFR PACC Mutations

The tyrosine kinase inhibitor firmonertinib showed promising efficacy in patients with non-small cell lung cancer across a broad range of EGFR PACC mutations in the first-line metastatic setting with CNS antitumor activity, according to research presented today at the International…